Spotlight on the 9-valent HPV vaccine
Pier Luigi Lopalco Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy Abstract: Starting in 2006, vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries. Two vaccines have been succ...
Saved in:
Main Author: | Lopalco PL (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-marketing study design to evaluate the effectiveness of the 9-valent and 4-valent HPV vaccines on serious HPV-related cervical disease in China
by: Yu Yang, et al.
Published: (2024) -
Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine
by: Ana Maria Guevara, et al.
Published: (2019) -
Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
by: André B. Kind, et al.
Published: (2020) -
Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
by: Tak Hong Cheung, et al.
Published: (2023) -
A survey of potential acceptance of 9-valent HPV vaccine among Chinese male college students
by: Shu Jia, et al.
Published: (2023)